ReviewMedicina (Kaunas, Lithuania)2022
Polypharmacy in Older Adults with Alzheimer's Disease.
Review in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Brexpiprazole for agitation in clinically relevant patient subgroups: aCurrent medical research and opinion · 2025Trial
- Theoretical impact of a mobile team dedicated to patients with Alzheimer's disease and related dementias on medication exposure in community-dwelling older patients (MEMORIAS study).BMC geriatrics · 2026Article
- Prescription cascades associated with acetylcholinesterase inhibitors use: a high-throughput sequence symmetry analysis.Age and ageing · 2026Article
- Effects of bright light therapy on cognition, sleep and psychological stress in older adults with mild-to-moderate cognitive impairment: a pilot study in long-term care facilities.BMC geriatrics · 2026Article
- Integrative analysis of cerebrospinal fluid biomarkers, metabolomics, and polygenic risk reveals novel metabolite associations with Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
- Trends in mortality from Alzheimer's disease and related dementias with hyperlipidemia in the United States from 1999 to 2020-a CDC WONDER database study.Frontiers in neurology · 2025Article
- Regulation of aging-related chronic diseases by dietary polyphenols: An updated overview.Current research in food science · 2025Review
- Prevalence of Value-Based Care for Older People with Dementia Likely to Be Nearing End of Life: A Hospital Retrospective Cohort.Healthcare (Basel, Switzerland) · 2024Article
- Highly prevalent geriatric medications and their effect on β-amyloid fibril formation.BMC neurology · 2024Article
- Association between Polypharmacy and Adverse Events in Patients with Alzheimer's Disease: An Analysis of the Japanese Adverse Drug Event Report Database (JADER).Medicina (Kaunas, Lithuania) · 2024Article
- Alzheimer's disease with depressive symptoms: Clinical effect of intermittent theta burst stimulation repetitive transcranial magnetic stimulation.World journal of psychiatry · 2024Article
- Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer's Disease.Brain sciences · 2024Review
- Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.BMJ (Clinical research ed.) · 2024Article
- Falls and Alzheimer Disease.Advances in geriatric medicine and research · 2024Article
- Two Years of Active Pharmacovigilance Surveillance and Therapeutic Reconciliation in Frail Populations: The MEAP 3.0 Study.Journal of clinical medicine · 2023Article
- Falls and Sleep Disorders in Spanish Alzheimer's Disease in Nursing Homes: An Observational Study.Healthcare (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of patients with Alzheimer's disease is increasing annually. Most of these patients are older adults with comorbid physical illnesses, which means that they are often treated with a combination of medications for the disease they have and those for Alzheimer's disease. Thus, older adults with Alzheimer's disease are potentially at risk for polypharmacy. In addition, the drug interactions between Alzheimer's disease medications and those for the treatment of physical illnesses may reduce their efficacy and increase side effects. This article reviews polypharmacy and drug interactions in elderly patients with Alzheimer's disease, with a focus on psychotropic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.